Advanced

OARSI/OMERACT Criteria of Being Considered a Candidate for Total Joint Replacement in Knee/Hip Osteoarthritis as an Endpoint in Clinical Trials Evaluating Potential Disease Modifying Osteoarthritic Drugs

Dougados, Maxime; Hawker, Gillian; Lohmander, Stefan LU ; Davis, Aileen M.; Dieppe, Paul; Maillefert, Jean-Francis and Gossec, Laure (2009) 9th International Consensus Conference on Outcome Measures in Rheumatology Clinical Trails (OMERACT 9) In Journal of Rheumatology 36(9). p.2097-2099
Abstract
Objective. A disease-modifying osteoarthritic drug (DMOAD) should interfere with the cartilage breakdown observed and improve symptoms or prevent deterioration of the patient's clinical condition. We propose a composite index including structural and symptomatic variables of osteoarthritis (OA) as criteria for being considered a candidate for total joint replacement as an endpoint in clinical trials evaluating potential DMOAD. Methods. An OARSI/OMERACT task force conducted this study in 3 steps: (1) The 3 main domains - pain, function, structure - were revisited; (2) For each of the domains a "non-acceptable state" and a "relevant" progression for their structure were defined; and (3) a set of criteria was proposed combining the... (More)
Objective. A disease-modifying osteoarthritic drug (DMOAD) should interfere with the cartilage breakdown observed and improve symptoms or prevent deterioration of the patient's clinical condition. We propose a composite index including structural and symptomatic variables of osteoarthritis (OA) as criteria for being considered a candidate for total joint replacement as an endpoint in clinical trials evaluating potential DMOAD. Methods. An OARSI/OMERACT task force conducted this study in 3 steps: (1) The 3 main domains - pain, function, structure - were revisited; (2) For each of the domains a "non-acceptable state" and a "relevant" progression for their structure were defined; and (3) a set of criteria was proposed combining the information from these 3 domains. Results. A questionnaire was elaborated for the domains "pain" and "function." Systematic research of the literature and evaluation of different databases concluded that the domain "structure" should be evaluated by radiological joint space width in millimeters. An unacceptable radiographic progression was defined as a change in the joint space width over the measurement error. An international, cross-sectional study is proposing a definition of a "nonacceptable symptom state." Conclusion. The objective of the ongoing OARSI/OMERACT initiative is to propose criteria for being considered a candidate for total joint replacement to be used as an endpoint in clinical trials evaluating potential DMOAD. The preliminary steps of this initiative have been completed. (J Rheumatol 2009;36:2097-9; doi:10.3899/jrheum.090365) (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Chapter in Book/Report/Conference proceeding
publication status
published
subject
keywords
ANTI-OSTEOARTHRITIC DRUGS, OSTEOARTHRITIS, TOTAL JOINT REPLACEMENT
in
Journal of Rheumatology
volume
36
issue
9
pages
2097 - 2099
publisher
J Rheumatol Publ Co
conference name
9th International Consensus Conference on Outcome Measures in Rheumatology Clinical Trails (OMERACT 9)
external identifiers
  • wos:000269677600045
  • scopus:70349259391
ISSN
1499-2752
0315-162X
DOI
10.3899/jrheum.090365
language
English
LU publication?
yes
id
2508f624-e548-4758-b7c4-a30ba85bd746 (old id 1492301)
date added to LUP
2009-10-16 17:09:33
date last changed
2017-10-22 03:40:50
@inproceedings{2508f624-e548-4758-b7c4-a30ba85bd746,
  abstract     = {Objective. A disease-modifying osteoarthritic drug (DMOAD) should interfere with the cartilage breakdown observed and improve symptoms or prevent deterioration of the patient's clinical condition. We propose a composite index including structural and symptomatic variables of osteoarthritis (OA) as criteria for being considered a candidate for total joint replacement as an endpoint in clinical trials evaluating potential DMOAD. Methods. An OARSI/OMERACT task force conducted this study in 3 steps: (1) The 3 main domains - pain, function, structure - were revisited; (2) For each of the domains a "non-acceptable state" and a "relevant" progression for their structure were defined; and (3) a set of criteria was proposed combining the information from these 3 domains. Results. A questionnaire was elaborated for the domains "pain" and "function." Systematic research of the literature and evaluation of different databases concluded that the domain "structure" should be evaluated by radiological joint space width in millimeters. An unacceptable radiographic progression was defined as a change in the joint space width over the measurement error. An international, cross-sectional study is proposing a definition of a "nonacceptable symptom state." Conclusion. The objective of the ongoing OARSI/OMERACT initiative is to propose criteria for being considered a candidate for total joint replacement to be used as an endpoint in clinical trials evaluating potential DMOAD. The preliminary steps of this initiative have been completed. (J Rheumatol 2009;36:2097-9; doi:10.3899/jrheum.090365)},
  author       = {Dougados, Maxime and Hawker, Gillian and Lohmander, Stefan and Davis, Aileen M. and Dieppe, Paul and Maillefert, Jean-Francis and Gossec, Laure},
  booktitle    = {Journal of Rheumatology},
  issn         = {1499-2752},
  keyword      = {ANTI-OSTEOARTHRITIC DRUGS,OSTEOARTHRITIS,TOTAL JOINT REPLACEMENT},
  language     = {eng},
  number       = {9},
  pages        = {2097--2099},
  publisher    = {J Rheumatol Publ Co},
  title        = {OARSI/OMERACT Criteria of Being Considered a Candidate for Total Joint Replacement in Knee/Hip Osteoarthritis as an Endpoint in Clinical Trials Evaluating Potential Disease Modifying Osteoarthritic Drugs},
  url          = {http://dx.doi.org/10.3899/jrheum.090365},
  volume       = {36},
  year         = {2009},
}